Home
overview

SMi proudly presents the 4th Annual Ophthalmic Drugs Conference taking place on the 22nd-23rd of November 2021, in London.

The global ophthalmic drug market is forecast to surpass $60 billion USD by 2025 with increasing focus from the industry on alternative delivery approaches and improving the effectiveness of the current repertoire of drugs in order to grow away from intravitreal injections and other surgical approaches to ocular therapy. With 50% of the global population predicted to have complications in their sight within the next few decades, ophthalmic medicine is set to become one of the biggest industries in pharmaceuticals.

As Europe’s leading Ophthalmic Drugs conference, we will explore new discoveries in the treatment of ocular disease, innovations in combination technologies, and the utterly unique challenges that are faced in the treatment of one of the most complex organs in the body.

This two-day agenda will offer peer-to-peer networking opportunities with leaders in the ophthalmic sphere, from Heads of Drug Development and Senior Directors of Ophthalmology, all the way to academic forerunners in the research into ocular therapy.

We look forward to welcoming you to the conference in November.

Early registration is strongly advised to avoid disappointment.

 

  • Insight into the newest techniques in ocular drug design and delivery
  • Explore the impacts and applications of controlled release technologies
  • Learn how advanced medical devices are changing the face of combined therapy
  • Understand the latest developments in overcoming the challenge of treating such a complex organ
     

 

Aerie Pharmaceuticals; Alcon Management SA; Boehringer Ingelheim Biopharmaceuticals Gmbh; Carl Zeiss AG; Centro de Oftamologia Barraquer; Experimentica Ltd; Eyenuk; Global Ophthamology R&D, Santen Inc, USA; Graybug Vision Inc; iVeena; Iveric Bio; Kingston University; Kingston University London; Medicines & Healthcare products Regulatory Agency (MHRA); Medivis; MedPharm Ltd; MHRA; Nanoptima Ltd; Newcastle University; Novartis Pharmaceutical inc; Ophthalmic Drugs 2019; Ophthalmology Times Europe; Optceutics Ltd; ProMed Pharma, LLC; ProQR Therapeutics; RAFARM S.A. Pharmaceuticals; Roche; Roche Products Limited; Santen UK; Spark Therapeutics; Thea Open Innovation; Topivert; twoXAR; UCL Institute of Ophthalmology; UCL School of Pharmacy and UCL Institute of Ophthalmology; University of Oxford; University of Reading; University of Strathclyde;

Conference programme

8:00 Registration & Coffee

9:00 Chairman's Opening Remarks

Mitchell De Long

Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
View Bio

9:10 Ocular gene therapy update

Daniel  Chung

Daniel Chung, Global Medical Strategy Lead-Ophthalmology, Spark Therapeutics

• The basic tenets of ocular gene therapy
• Update on current ocular gene therapy
• The future of ocular gene therapy

9:50 Novel upstream target inhibiting the NLRP3 inflammasome in geographic atrophy and diabetic retinopathy

Brian Levy

Brian Levy, CEO, Ocunexus Therapeutics
View Bio

• Disruptive and transformative potential for disease modification
• Xiflam - orally administered small molecule cx43 hemichannel inhibitor
• MOA and Xiflam efficacy demonstrated in phenotypical models of disease (GA, DR)
• Target Cx43 hemichannel is present in human tissue with disease (AMD and DR)
• MOA confirmed in ex vivo human cadaver retinas with diseases of interest
• In Phase 2B clinical studies by Q4/20

10:30 Morning Coffee

11:00 From the trabecular meshwork to the retina - Ophthalmological research at Aerie

Mitchell De Long

Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
View Bio

• Summary of Aerie's Rock Inhibitors for glaucoma, including plans for Europe and Japan
• Aerie's ongoing clinical studies for retinal diseases, including the clinical candidates AR-1105 and AR-13503
• Future outlook for glaucoma treatment and for long-term ocular dosing for the treatment of retinal disease

11:40 The EpiSmart System for transepithelial corneal collagen cross-linking in Keratoconus

Jonathan  Talamo

Jonathan Talamo, Health Care Executive, Consultant, and Board Member, CXL Ophthalmics
View Bio

• Key ingredients for epithelium – on crosslinking
• The EpiSmart System
• Clinical results & implications for future treatment paradigms

12:20 Networking Lunch

13:20 Design and characteristics of a sustained release local ocular formulation of carboxyamidotriazole, a safe and effective antiangeogenic with a novel mechanism of action

Alan Franklin

Alan Franklin, CEO, ForwardVue Pharma
View Bio

• Established systemic safety in cancer trials
• Safety and efficacy in ocular preclinical models
• Novel mechanism of action, ORAI1 inhibition
• Design and characteristics of durable local ocular formulation

14:00 Ocular tolerability and formulation toxicity in drug development

Virginia Calder

Virginia Calder, Reader in Ocular Immunology, UCL Institute of Ophthalmology
View Bio

• In vivo and In vitro models for tolerability and toxicity
• Characterising the physical and biological stability of new ocular therapies
• The in vivo toxicity of Brolucizumab in the macula
• Advances in cationic emulsions to moderate dry eye disease

14:40 Afternoon Tea

15:10 Developments in the treatment of glaucoma

Simon Chandler

Simon Chandler, Executive Director, Clinical Development, Allergan Ltd

• The latest approved drugs and the newest therapies on the horizon
• Implants in Glaucoma treatment
• The current landscape of retinoprotection and glaucoma mitigation strategy
• Ensuring stable intraocular pressure and maintaining patient compliance

15:50 Recent advancements in the formulation and delivery of APIs to the ocular surface and anterior segment of the eye

Ali  Athab Al-Kinani

Ali Athab Al-Kinani, Senior Lecturer in Clinical Pharmaceutics, Kingston University
View Bio

• Glaucoma and cataract are the two leading causes for blindness worldwide, whereas dry eye is the most widely treated eye condition
• Conventional dosage forms, mainly in the form of eye drops and surgery are still widely used to manage these conditions
• Conventional treatment offers poor efficacy, whilst surgery is associated with complications and is not readily available to patients in developing countries
• There is a need for innovative delivery technologies to overcome these issues
 

16:30 Chairman’s Closing Remarks and Close of Day One

Mitchell De Long

Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
View Bio

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Mitchell De Long

Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
View Bio

9:10 Diabetic Macular Ischaemia: A hidden unmet medical need

Victor Chong

Victor Chong, Global Head of Medicine, Retinal Health, Boehringer Ingelheim Pharma GmbH & Co. KG
View Bio

• Diabetic retinopathy is a leading cause of working age blindness
• With the advances of vitrectomy and anti-VEGF, why do patients continue to go blind?
• Diabetic macular ischaemia can now be measured
• Why not have more companies working on that?

9:50 Development of Lumevoq gene therapy in Leber Hereditary Optic Neuropathy (LHON) subjects

Magali Taiel

Magali Taiel, Chief Medical Officer , Gensight-Biologic

• Key clinical development steps
• EMA & FDA regulatory pathways
• Results of two pivotal studies
• Key learnings and next steps

10:30 Morning Coffee

11:00 Adapting to the changing landscape of AAV gene therapy for retinal disorders

Ian Catchpole

Ian Catchpole, Chief Scientific Officer, Horama

• Bullet points to be confirmed

11:40 Ocular delivery of small molecules and biologics using long-acting injectable photocrosslinked implants

Thakur Raghu Raj Singh

Thakur Raghu Raj Singh, Reader in Pharmaceutics, Founder and CTO Re-Vana Therapeutics, Chair for Ocular Delivery Focus Group, Queen's University Belfast
View Bio

• Intravitreal injections and eye drops offer little ocular bioavailability - leading to frequent administrations and poor patient compliance
• Innovative solutions are needed to address the unmet need in ocular delivery of molecules
• Understanding current challenges and engineering new delivery systems
• Insight into novel photocrosslinked in situ depot forming and preformed implants

12:20 Networking Lunch

13:20 Part 1. Evolution of ocular surface antibiotics and what the future might hold

Harminder Dua

Harminder Dua, Chair and Professor of Ophthalmology, The University of Nottingham
View Bio

• Brief account of medicines and dispensing devices used by ancient Egyptians
• Development of modern antibiotics
• The problem of antibiotic resistance
• The future with newer drugs and the promise of antimicrobial peptides

Part 2. Preserved eye drops, are we preserving the eyes?
• Brief account of various ingredients of eye drops and their purpose
• Range of preservatives used
• Effect of preservatives on eye structures
• Preservative free drops, where we are
 

14:00 Non-viral gene therapy for the prolonged delivery of proteins in the eye

Francine Behar-Cohen

Francine Behar-Cohen, Chief Innovation Officer, Eyevensys
View Bio

• Eyevensys develops a non-viral gene therapy combined therapy to deliver plasmids encoding any therapeutic proteins in the ciliary muscle
• A simple procedure using a disposable device and an external application has been developed
• Sustained protein production in the eye has been demonstrated
• Phase I/II study has demonstrated the safety of the procedure- Phase II studies ongoing in Europe and in the US
 

14:40 Afternoon Tea

15:10 Nanomaterials for posterior segment drug delivery

Laurence  Fitzhenry

Laurence Fitzhenry, Lecturer & Project Coordinator, ORBITAL-ITN
View Bio

• Outline of the ORBITAL network
• Specific examples of nano/micro technologies for ophthalmic delivery
• Challenges associated with posterior segment delivery
• Outline of the projects and focus of the ORBITAL-ITN

15:50 An overview of targeted delivery of pharmacological agents using suprachoroidal injection

Colette  Hall

Colette Hall, Vice President of Medical and Safety, Clearside BioMedical, Inc.
View Bio

• Overview of drug delivery via Suprachoroidal Injection procedure
• Experience with suprachoroidal delivery of CLS-TA
• Additional applications of suprachoroidal delivery for different therapies (e.g. Small molecules, gene therapy, etc)

16:30 Chairman’s Closing Remarks and Close of Day Two

Mitchell De Long

Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
View Bio

+

FEATURED SPEAKERS

Alan Franklin

Alan Franklin

CEO, ForwardVue Pharma
Brian Levy

Brian Levy

CEO, Ocunexus Therapeutics
Daniel  Chung

Daniel Chung

Global Medical Strategy Lead-Ophthalmology, Spark Therapeutics
Francine Behar-Cohen

Francine Behar-Cohen

Chief Innovation Officer, Eyevensys
Harminder Dua

Harminder Dua

Chair and Professor of Ophthalmology, The University of Nottingham
Ian Catchpole

Ian Catchpole

Chief Scientific Officer, Horama
Jonathan  Talamo

Jonathan Talamo

Health Care Executive, Consultant, and Board Member, CXL Ophthalmics
Laurence  Fitzhenry

Laurence Fitzhenry

Lecturer & Project Coordinator, ORBITAL-ITN
Magali Taiel

Magali Taiel

Chief Medical Officer , Gensight-Biologic
Mitchell De Long

Mitchell De Long

Vice President, Chemistry, Aerie Pharmaceuticals
Simon Chandler

Simon Chandler

Executive Director, Clinical Development, Allergan Ltd
Thakur Raghu Raj Singh

Thakur Raghu Raj Singh

Reader in Pharmaceutics, Founder and CTO Re-Vana Therapeutics, Chair for Ocular Delivery Focus Group, Queen's University Belfast
Victor Chong

Victor Chong

Global Head of Medicine, Retinal Health, Boehringer Ingelheim Pharma GmbH & Co. KG
Virginia Calder

Virginia Calder

Reader in Ocular Immunology, UCL Institute of Ophthalmology

Alan Franklin

CEO, ForwardVue Pharma
Alan Franklin

During Retinal Fellowship at University of Iowa, Dr. Franklin secured both HEED and HEED-Knapp scholarships. His research work on an anti-vascular agent as a candidate to treat retinal diseases such as diabetic retinopathy and age-related macular degeneration was awarded the best research project by an ophthalmic physician in training at the 1999 Association of University Professors in Ophthalmology meeting. Dr. Franklin has continued his interest and progress in the treatment of diabetic retinopathy and age-related macular degeneration (AMD) in his vitreoretinal practice. He is founder and CEO of ForwardVue Pharma, and also consults to develop retinal surgical visualization.

Ali Athab Al-Kinani

Senior Lecturer in Clinical Pharmaceutics, Kingston University
Ali  Athab Al-Kinani

Ali Athab Al-Kinani is a senior lecturer in Clinical Pharmaceutics at Kingston University, London. He leads research groups in ophthalmic drug delivery where his research is tackling aging related eye diseases such as cataract and glaucoma. Furthermore, Ali’s research is looking at improving drugs’ bioavailability on the ocular and anterior segment of the eye using novel delivery systems and formulations.

His high standard research was acknowledged nationally and internationally where he was an awardee of several national and international research awards such as the American Association of Pharmaceutical Scientists (AAPS).

 

Brian Levy

CEO, Ocunexus Therapeutics
Brian Levy

CEO of Ocunexus Therapeutics a clinical stage company developing products targeting the innate NLRP3 inflammasome in pathological autoinflammation
Chief Medical Officer Aerie Pharmaceuticals - 2 Rho Kinase Inhibitors for lowering of IOP in Glaucoma Approved and commercialized.
VP of R&D and Chief Medical Officer Bausch & Lomb 15 years 3 NDA’s;
Retisert - the first approved intravitreal Drug Delivery System for Posterior Uveitis
Zylet - topical steroid/antibiotic for ophthalmic infection/inflammation
Bezivance - 4th generation fluoroquinolone for ocular bacterial infection
Multiple device approvals; IOL’s, Cataract, Retinal, Refractive Surgical Equipment, Contact Lenses
Associate Professor, Ophthalmology, CPMC San Francisco, Private Practice Toronto, Clinical investigator consultant to the ophthalmic industry. 60 peer reviewed publications presented globally major meetings. O.D. at UC Berkeley, M.Sc. Comparative Ocular Physiology University Waterloo. On boards of 3 startups.
 

Colette Hall

Vice President of Medical and Safety, Clearside BioMedical, Inc.
Colette  Hall

Colette Hall is the Vice President of Medical and Safety at Clearside Biomedical and maintains U.S. Board certification in Internal Medicine. Previously, Dr. Hall served as a Medical Safety Advisor at IQVIA for over 8 years. During her time at IQVIA, Dr. Hall led both clinical and safety teams providing medical review, oversight and strategy for over 90 companies, both small and large, executing over 100 protocols across multiple indications. Additionally, she provided signal detection services, post marketing surveillance, protocol review and development, and review of aggregate reports. Prior to joining IQVIA, Dr. Hall also served as a Principal Investigator on 5 clinical trials in the following areas: diabetes, hyperlipidemia, and atrial fibrillation. She also maintained a solo primary care practice where she successfully managed and provided medical care to over 2500 patients. Dr. Hall is an active member of the American Medical Association and American College of Physician. She graduated from Duke University and Meharry Medical College, followed by an internship and residency at Atlanta Medical Center.

Daniel Chung

Global Medical Strategy Lead-Ophthalmology, Spark Therapeutics
Daniel  Chung

Francine Behar-Cohen

Chief Innovation Officer, Eyevensys
Francine Behar-Cohen

Francine Behar-Cohen is a retina specialist at Cochin Hospital, Paris University hospital. She heads an Inserm team of basic and clinician scientists since 2001. As an expert for ANSES (the French Agency for Food, Environmental and Occupational Health & Safety), she was president of the GT_LED1 for the evaluation of the ocular toxicity of LED (2010) of 3D (2014) and for all LED applications (2018). From 2013 to 2017, she was the chairwoman of the Jules Gonin Eye hospital. She created Optis France, in 1999 that became Eyegate Pharma for ocular iontophoresis, Eyevensys in 2012, for non-viral gene therapy for retinal diseases. She serves as Chief Innovation Officer in Eyevensys.

Harminder Dua

Chair and Professor of Ophthalmology, The University of Nottingham
Harminder Dua

MBBS, DO, DO(London), MS, MNAMS, FFMLM, FRCS(Edinburgh), FEBO, FRCOphth, FRCP(Edinburgh, Hon.), FCOptom.(Hon.), FRCOphth.(Hon.), FAICO(Hon.), MD, PhD, is Chair and Professor of Ophthalmology at the Queens Medical Centre, University of Nottingham since 1994 and joint Head-of-Service, since January 2018. He is also Honorary Professor of Universita della Svizze, Lugano.
He was made Commander of the most excellent order of the British Empire by Her Majesty Queen Elizabeth II in her 2019 Birthday Honours list. He is High Sheriff of Nottinghamshire in nomination, to assume office in 2021.
He is Editor-in-chief of the Journal of EuCornea, President of The European association for vision and eye research Foundation, member of the Academia Ophthalmologica Internationalis and the American Ophthalmological Society and immediate past Master of the Oxford Ophthalmological Congress, UK. He was the 9th President of the Royal College of Ophthalmologists UK (2011-14) and has served as Editor-in-Chief of the British Journal of Ophthalmology (2007-14); President of EuCornea (2011-13), President of the European association for vision and eye research (EVER, 2008) and of the EVER Foundation (2010-14).
 

Ian Catchpole

Chief Scientific Officer, Horama
Ian Catchpole

Jonathan Talamo

Health Care Executive, Consultant, and Board Member, CXL Ophthalmics
Jonathan  Talamo

Jonathan H. Talamo, M.D. is an experienced surgeon and thought leader in ophthalmology, particularly in the areas of corneal disease, cataract and refractive surgery. He has served as a consultant or board member to numerous companies in the biopharma, medical device and health care delivery sectors. Dr. Talamo currently advises early stage companies as a consultant or Board Director. He previously served as Chief Medical Officer at Ocular Therapeutix, where he played an important role in the development of Dextenza (extended release dexamethasone ophthalmic insert) and, most recently, at Johnson and Johnson Vision, where he helped lead the integration of Abbott Medical Optics as well as the development and launch of numerous innovative products.

Laurence Fitzhenry

Lecturer & Project Coordinator, ORBITAL-ITN
Laurence  Fitzhenry

Dr. Laurence Fitzhenry is a Lecturer in Chemistry at the Department of Science, Waterford Institute of Technology and Principal Investigator of the Ocular Therapeutics Research Group (OTRG) at the PMBRC.
He received his PhD in polymer and analytical chemistry from WIT in 2011, where he conducted his postdoctoral research on the development of contact lenses for the controlled release of pharmaceutical actives.
Laurence is the project co-ordinator for the MSCA-funded ORBITAL-ITN, a global consortium focused on training researchers in the development of innovative strategies for posterior segment drug delivery to the eye.

Magali Taiel

Chief Medical Officer , Gensight-Biologic
Magali Taiel

Mitchell De Long

Vice President, Chemistry, Aerie Pharmaceuticals
Mitchell De Long

Mitchell A. (Mitch) deLong holds the position of vice president, Chemistry at Aerie Pharmaceuticals as well as Adjunct Professor of Chemistry at Duke University. Since Mitch helped to found Aerie as a Duke University spinout in 2005, Aerie has filed 6 INDs and 2 NDAs, with its first FDA approval coming in 2017, and its second less than 18 months later. Aerie has grown from the initial 3-person team to over 300 employees and went public on NASDAQ in 2013. Mitch is lead inventor on over 60 issued US patents, about half of those at Aerie, and has over 100 publications, posters and presentations, including co-chairing all three of SMI’s Ophthalmic Drugs’ Conferences. Mitch earned his PhD in Synthetic Organic and Medicinal Chemistry at Stanford University, and has two other marketed drugs, unrelated to ophthalmology to his credit.

Simon Chandler

Executive Director, Clinical Development, Allergan Ltd
Simon Chandler

Thakur Raghu Raj Singh

Reader in Pharmaceutics, Founder and CTO Re-Vana Therapeutics, Chair for Ocular Delivery Focus Group, Queen's University Belfast
Thakur Raghu Raj Singh

Dr Raj Thakur is a Reader in Pharmaceutics at the School of Pharmacy (SoP), QUB and is the Founder, CTO and Director of Re-Vana Therapeutics. His research interest is in the design and physicochemical characterisation of advanced long-acting biodegradable drug delivery systems including minimally invasive medical devices for localised drug delivery. He is the Chair for Ocular Drug Delivery (OcDD) Focus Group supported by the mission of Controlled Release Society (CRS). He has authored over 160 scientific publications, including 60 full papers, 10 book chapters, five textbooks, several invited talks in national and international conferences and patents. To date, he has secured funding of approx. £5 million research funding.

Victor Chong

Global Head of Medicine, Retinal Health, Boehringer Ingelheim Pharma GmbH & Co. KG
Victor Chong

Victor Chong is a retinal specialist with a special interest in macular diseases. He is the Global Head of Medicine, Retinal Health, Boehringer Ingelheim International GmbH; Consultant, Optegra Eye Hospital, London and Honorary Consultant, Royal Free Hospital, London. Before joining BI in 2016, he was Head of Department at Oxford Eye Hospital, Oxford University Hospitals. BI Retinal Health currently has 4 molecules in clinical phase in diabetic retinopathy, wet AMD, GA and diabetic macular ischaemia. He received his medical degree from University of Glasgow, his doctoral degree from King’s College, London, and MBA from Quantic SBT, Washington DC.

Virginia Calder

Reader in Ocular Immunology, UCL Institute of Ophthalmology
Virginia Calder

Professor Calder is a T-cell immunologist with considerable experience in inflammatory eye diseases (posterior uveitis, atopic and vernal keratoconjunctivitis). Immunosuppressive drugs can be effective but often have devastating side-effects, especially for the eye, when taken long term. The focus of her research is to investigate underlying immune mechanisms and potential novel therapeutic targets. This involves utilizing relevant experimental models of disease and validating results with clinically well-defined donor specimens, including conjunctival tissues, aqueous humor, tear fluids, peripheral blood and serum. She has considerable expertise in determining the toxicity and therapeutic efficacy of novel compounds in vitro and in vivo, in her research collaborations with Pharma

Sponsors and Exhibitors

Official Media Partner

Supporting Media Partners

Supporters

Workshops

Novel Platforms in Ocular Drug Delivery
Workshop

Novel Platforms in Ocular Drug Delivery

Venue To Be Confirmed
24th November 2021
London, United Kingdom

Ophthalmic Drug Delivery Development - Trials and Tribulations
Workshop

Ophthalmic Drug Delivery Development - Trials and Tribulations

Venue To Be Confirmed
24th November 2021
London, United Kingdom

VENUE

Venue To Be Confirmed

London, United Kingdom

A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
HOTEL BOOKING FORM

SPEAKER INTERVIEW WITH VICTOR CHONG, Boehringer Ingelheim Pharma

Download

SPEAKER INTERVIEW - ALAN FRANKLIN, CEO, ForwardVue Pharma

Download

Chair letter

Download

Speaker Interview - MAGALI TAIEL, GENSIGHT-BIOLOGIC

Download

Ophthalmic Drugs Infographic

Download

William Dallman – Eyenuk, PAST PRESENTATION

Download

Virginia L. Calder, PhD, UCL, PAST PRESENTATION

Download

Dr Che John Connon , Newcastle University, PAST PRESENTATION

Download

AARON C DAUGHERTY, TWOXAR, PAST PRESENTATION

Download

Pete Morgan-Warren, MHRA, PAST PRESENTATION

Download

Sponsors and Exhibitors


Experimentica

Sponsors and Exhibitors
https://experimentica.com/

Experimentica combines expertise in Ophthalmology and preclinical ocular models with state of the art imaging and functional assessment capabilities.

As a global CRO we work with Pharmaceutical Companies, Biotechs, and Academia. Our solutions bridge the gap between the development of new models and their use in developing clinical applications.


Media Partners


Eye News

Official Media Partner
https://www.eyenews.uk.com/

Eye News, both in print and online, provides a comprehensive tour of the wide range of current issues facing all eye care professionals. Ever issue is written by key opinion leaders in the field and includes clinical features, commentary, overviews of the key recent academic papers, book reviews and industry news. The magazine boasts a comprehensive training and conference diary in addition to in-depth conference reports and a monthly events enewsletter. The magazine gives a breadth of filtered information on all aspect of ophthalmology specialist and key related issues and subscription is free to readers in the UK. “Time is precious and we pride ourselves at Eye News in the task of scouring the land to secure acknowledged experts to give practical and pragmatic advice, teaching the reader in an entertaining and informative way” Prof Bal Dhillon, Editor, Prof of Clinical Ophthalmology, University of Edinburgh and Hon Consultant Princess Alexandra Eye Pavilion, Edinburgh https://www.eyenews.uk.com/


Ophthalmology Times Europe

Official Media Partner
http://europe.ophthalmologytimes.com/

Ophthalmology Times Europe, is a physician-driven media brand that presents cutting-edge advancements from around the world in surgery, clinical diagnosis, drug therapy, and technology to elevate the delivery of progressive eye health from physician to patient.


ONdrugDelivery Magazine

Official Media Partner
http://ondrugdelivery.com

ONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe.

Media Partners


Experimentica

Supporting Media Partners
http://www.experimentica.com

Experimentica Ltd. is a global company and the largest ophthalmic CRO in Northern Europe, striving to provide scientific excellence by relying entirely on in-house expertise. Experimentica Ltd. is headquartered in Kuopio, Finland with offices in Tampere, Finland, Chicago, IL, USA, Shanghai, China, and R&D site in Vilnius, Lithuania. For more information, visit www.experimentica.com.


Pharma Journalist

Supporting Media Partners
http://www.pharmajournalist.com

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


ProMed Pharma

Supporting Media Partners
http://www.promedpharmallc.com

ProMed Pharma specializes in the molding of drug-loaded silicones and thermoplastics and leverages this expertise to manufacture long-term implants and combination devices under cGMP. Working with established and early stage companies, we utilize robust manufacturing processes for controlled release of APIs utilizing a variety of materials. From clinical trial materials to commercial products, ProMed supports pharmaceutical and medical device companies developing controlled release formulations including subcutaneous, orthopedic, cardiovacular, and ophthalmic implants, intravaginal rings, and steroid-eluting components. Please visit www.promedpharmallc.com for more details.


Pharma network magazine

Supporting Media Partners
https://www.pharmanetwork.digital

PHARMAnetwork is a company specialized in publishing for the pharmaceutical industry. PHARMAnetwork has developed publications for CMO, CDMO and professionals working in the life sciences. PHARMAnetwork designs specialized studies for pharmaceutical companies, contract service providers and investment firms. PHARMAnetwork magazine covers, every aspect of pharmaceutical value chain, the change and developments in the intersection between pharmaceutical industry and outsourcing industry. We perform interviews and write articles whose thematic strategies, organizations, mergers and acquisitions, regulatory, innovation in the pharmaceutical development and contract manufacturing. https://www.pharmanetwork.digital


Gene Therapy Net

Supporting Media Partners
http://www.genetherapynet.com

Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines


eyetube

Supporting Media Partners
http://eyetube.net

Eyetube.net is ophthalmology’s leading source for high-quality, full-narrated ophthalmic surgical videos. The Web site was created by a panel of experts to better educate ophthalmologists through the online archiving and sharing of videos. Our mission is to foster a secure, engaging physician community across all sub-specialties powered by user-generated content, whether it be videos, discussion threads, or blogs.

Media Partners


Drug Discovery Today

Supporters
http://www.drugdiscoverytoday.com/

Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


IPI

Supporters
http://www.ipimediaworld.com

IPI – International Pharmaceutical Industry Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.


Farmavita

Supporters
https://farmavitar.com

FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Venue To Be Confirmed

London
United Kingdom

Venue To Be Confirmed

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out